Shaadi Mehr

Shaadi Mehr

Auto-generated profile, based on publicly available information

Shaadi Mehr

Multiple Myeloma Research Foundation, Norwalk, CT

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
CNChidimma Nzerem
Chidimma Nzerem
RRRobert Redd
Robert Redd
ADAndrew Dunford
Andrew Dunford
MLMatthew Leventhal
Matthew Leventhal
GGGad Getz
Gad Getz
Clonal hematopoiesis (CH) at time of autologous stem cell transplant (ASCT) has been shown to be associated with decreased overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma not receiving immunomodulatory drugs (IMiD). However, the significance of CH in newly diagnosed patients, including transplant ineligible patients, and its effect on clonal evolution during multiple myeloma therapy in the era of novel agents, has not been well studied. Using our new algorithm to differentiate tumor and germline mutations from CH, we detected CH in approximately 10% of 986 patients with multiple myeloma from the Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) cohort (40/529 transplanted and 59/457 non-transplanted patients). CH was associated with increased age, risk of recurrent bacterial infections and cardiovascular disease. CH at time of multiple myeloma diagnosis was not associated with inferior OS or PFS regardless of undergoing ASCT, and all patients benefited from IMiD-based therapies, irrespective of the presence of CH. Serial sampling of 52 patients revealed the emergence of CH over a median of 3 years of treatment, increasing its prevalence to 25%, mostly with DNMT3A mutations. Significance: Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and ineligible patients. Receiving IMiDs improved outcomes irrespective of CH status, but the prevalence of CH significantly rose throughout myeloma-directed therapy.

5 November 2020 in Blood
Verified
Journal Article
Open access
SMShaadi Mehr
Shaadi Mehr
DADaniel Auclair
Daniel Auclair
MHMark Hamilton
Mark Hamilton
LRLeon Rozenblit
Leon Rozenblit
HCHearn Jay Cho
Hearn Jay Cho
SMSergey Miron
Sergey Miron
Title: Architecture of sample preparation and data governance of Immuno-genomic data collected from bone marrow and peripheral blood samples obtained from multiple myeloma patients In multiple myeloma (MM), the interactions between malignant plasma cells and the bone marrow microenvironment is crucial to fully understand tumor development, disease progression, and response to therapy. The core challenge in understanding those interactions has been the establishment of a standard process and a standard model for handling the data quality workflow and the underlying data models. Here we present the Platform (Figure 1), an integrated data flow architecture designed to create data inventory and process tracking protocols for multi-dimensional and multi-technology immune data files. This system has been designed to inventory and track peripheral blood and bone marrow samples from multiple myeloma subjects submitted for immune analysis under the MMRF Immune Atlas initiative (figure 2), and the processing and storage of Single Cell RNA-seq (scRNA-seq) and Mass Cytometry time-of-flight (CyTOF) data files derived from these immune analyses. While these methods have been previously applied on both tumor and immune populations in MM [2,3], this level of multi-institutional and multi-technology is unique. The Cloud Immune-Precision platform contains standardized protocols and bioinformatics workflows for the identification and categorization of immune cell populations and functional states based upon scRNA-seq gene signatures (ref: Bioinformatics manuscript in submission) and CyTOF protein signatures. Upon further expansion, it will contain high dimensional scRNAseq and CyTOF immune data from both bone marrow and peripheral blood samples from myeloma patients enrolled in the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (NCT01454297) [1] (Figure 3). The architecture covers the automation of data governance protocols, data transformation and ETL model developments that will create an immune proteomic and profiling database and its integration into clinical and genomics databases: e.g. the MMRF CoMMpass clinical trial. This large-scale data integration will establish a cutting-edge Immune-Precision central platform supporting large scale, immune-focused advanced analytics in multiple myeloma patients. This platform will allow researchers to interrogate the relationships between immune transcriptomic and proteomic signatures and tumor genomic features, and their impact on clinical outcomes, to aid in the optimization of therapy and therapeutic sequencing. Furthermore, this platform also promotes the potential to (further) elucidate the mechanisms-of-action of approved and experimental myeloma therapies, drive biomarker discovery, and identify new targets for drug discovery. Figure 1: Cloud Immune-Precision Platform (Integrated data flow architecture designed to create data inventory and process tracking protocols for multi-dimensional and multi-technology immune data files) Figure 2: Sample tracking process architecture Figure 3: Data file creation and repository process tracking References: 1- Settino, Marzia et al. "MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers." Computational Science - ICCS 2020: 20th International Conference, Amsterdam, The Netherlands, June 3-5, 2020, Proceedings, Part III vol. 12139 564-571. 22 May. 2020, doi:10.1007/978-3-030-50420-5_42 2- Ledergor, Guy et al. "Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma." Nature medicine vol. 24,12 (2018): 1867-1876. doi:10.1038/s41591-018-0269-2 3- Hansmann, Leo et al. "Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma." Cancer immunology research vol. 3,6 (2015): 650-60. doi:10.1158/2326-6066.CIR-14-0236-T Figure 1 Disclosures Bhasin: Canomiiks Inc: Current equity holder in private company, Other: Co-Founder. Dhodapkar:Amgen: Membership on an entity's Board of Directors or advisory committees, Other; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Other; Janssen: Membership on an entity's Board of Directors or advisory committees, Other; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Other; Lava Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other; Kite: Membership on an entity's Board of Directors or advisory committees, Other.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KKKevin M. Keogh
Kevin M. Keogh
ABAndrew J. Belli
Andrew J. Belli
MMMonica M. Matta
Monica M. Matta
KTKathryn A. Tanenbaum
Kathryn A. Tanenbaum
KFKaeleigh Farrish
Kaeleigh Farrish
SLSteven E. Labkoff
Steven E. Labkoff
E19528 Background: Record retrieval on behalf of a consenting patient within the context of real-world data is not well understood. As the need for real-world data continues to expand, methods for the efficient transfer of information across consenting parties will be critical to enable research collaborations. This need was highlighted through a partnership between COTA and the Multiple Myeloma Research Foundation (MMRF). As one component of the pilot study, COTA managed the record retrieval of consenting patients before going on to abstract the data for use in a registry. Methods: The pilot study identified 23 patients that consented to the release of medical records at 54 institutions across 20 states. COTA partnered with a retrieval vendor and employed its own outreach efforts for acquisition. Outreach and retrieval techniques were similar across COTA and the vendor, including targeted calls, delivery of IRB-approved consent materials, and on-site requests. The 30-day release parameter for a covered entity under 45 CFR 164.524(b)(2) of HIPAA’s Privacy Rule was used to evaluate the observed return rates. Results: A total of 56 medical records were requested, and 48 records were retrieved. The mean (±SD) retrieval time across all sites was 33 (±58) days. We found that 54% of records were released in < = 30 days, and 32% of records > 30 days. 14% of requested records were never released, despite a median of 19 outreach attempts (range 10 to 43). Cited issues for delay or non-release consisted of 22 institutions questioning the validity of the certified electronic patient signature, 6 requiring a physical signature, and 5 requiring their own authorization forms. In no cases did the records contain structured metadata, such as LOINC, MedDRA, and RxNorm. Conclusions: This pilot showed an unpredictable variance associated with the release of records in the context of real-world data. This variance contributed to barriers and delays in broader research efforts. The lack of accompanying metadata with released records resulted in additional required data processing. Future studies should be conducted to establish best practices in the release and retrieval of medical records used to support real-world data research.

18 December 2023
Verified
Other
Open access
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
CNChidimma Nzerem
Chidimma Nzerem
RRRobert Redd
Robert Redd
ADAndrew Dunford
Andrew Dunford
MLMatthew Leventhal
Matthew Leventhal
GGGad Getz
Gad Getz
Clonal hematopoiesis (CH) at time of autologous stem cell transplant (ASCT) has been shown to be associated with decreased overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma not receiving immunomodulatory drugs (IMiD). However, the significance of CH in newly diagnosed patients, including transplant ineligible patients, and its effect on clonal evolution during multiple myeloma therapy in the era of novel agents, has not been well studied. Using our new algorithm to differentiate tumor and germline mutations from CH, we detected CH in approximately 10% of 986 patients with multiple myeloma from the Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) cohort (40/529 transplanted and 59/457 non-transplanted patients). CH was associated with increased age, risk of recurrent bacterial infections and cardiovascular disease. CH at time of multiple myeloma diagnosis was not associated with inferior OS or PFS regardless of undergoing ASCT, and all patients benefited from IMiD-based therapies, irrespective of the presence of CH. Serial sampling of 52 patients revealed the emergence of CH over a median of 3 years of treatment, increasing its prevalence to 25%, mostly with DNMT3A mutations.Significance:Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and ineligible patients. Receiving IMiDs improved outcomes irrespective of CH status, but the prevalence of CH significantly rose throughout myeloma-directed therapy.

18 December 2023
Verified
Other
Open access
Tarek MouhieddineTarek Mouhieddine
Tarek Mouhieddine
CNChidimma Nzerem
Chidimma Nzerem
RRRobert Redd
Robert Redd
ADAndrew Dunford
Andrew Dunford
MLMatthew Leventhal
Matthew Leventhal
GGGad Getz
Gad Getz
Clonal hematopoiesis (CH) at time of autologous stem cell transplant (ASCT) has been shown to be associated with decreased overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma not receiving immunomodulatory drugs (IMiD). However, the significance of CH in newly diagnosed patients, including transplant ineligible patients, and its effect on clonal evolution during multiple myeloma therapy in the era of novel agents, has not been well studied. Using our new algorithm to differentiate tumor and germline mutations from CH, we detected CH in approximately 10% of 986 patients with multiple myeloma from the Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) cohort (40/529 transplanted and 59/457 non-transplanted patients). CH was associated with increased age, risk of recurrent bacterial infections and cardiovascular disease. CH at time of multiple myeloma diagnosis was not associated with inferior OS or PFS regardless of undergoing ASCT, and all patients benefited from IMiD-based therapies, irrespective of the presence of CH. Serial sampling of 52 patients revealed the emergence of CH over a median of 3 years of treatment, increasing its prevalence to 25%, mostly with DNMT3A mutations.Significance:Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and ineligible patients. Receiving IMiDs improved outcomes irrespective of CH status, but the prevalence of CH significantly rose throughout myeloma-directed therapy.